Table 1. Molecular abnormalities in SCLC and LCNEC.
| Variable | SCLC (%) | LCNEC (%) | References |
|---|---|---|---|
| CGH | |||
| Loss | 3p, 4q, 5q, 13q, 10q, 16q, 17p | 3p, 4q, 5q, 13q | (39) |
| Gain | 5p, 3q | 5p, 6p | (39) |
| LOH | 3p, 5q11, 5q21, 5q33, 10p, 10q, 13q, 17p | 3p, 5q11, 9p, 10p, 10q, 13q, 17p | (40,41) |
| Mutation | |||
| TP53 | 75–94 | 71–95 | (1,19,42-46) |
| RB1 | 40–91 | 26–38 | (19,42,44-46) |
| CREBBP | 17 | 6 | (19,47) |
| EP300 | 10 | 0 | (19,47) |
| MLL | 10 | 8 | (19,47) |
| KEAP1 | N/A | 31 | (19) |
| STK11 | 0 | 16–33 | (43,48) |
| KRAS | 0–2 | 4–24 | (14,19,41-43,49-51) |
| BRAF | 0–1 | 0 | (1,43,49) |
| EGFR* | 0–7 | 0–4 | (14,19,42,49-52) |
| PTEN | 2–10 | 4–13 | (42,43,46,53) |
| PIK3CA | 1–13 | 3–4 | (1,42,43,49,50) |
| FGFR1 | 3–7 | 5 | (42) |
| AKT1 | 0 | 0 | (19,50) |
| AKT2 | 2 | 0–4 | (19,42) |
| LAMA1 | 2 | 10 | (42) |
| PCLO | 1 | 6 | (42) |
| MEGF8 | 0 | 5 | (42) |
| RICTOR | 6 | 4–5 | (19,42) |
| mTOR | N/A | 1–2 | (19,42) |
| KIT | 1–2 | 4–13 | (1,42,43) |
| Rearrangement | |||
| ALK | 0 | 0–2 | (14,43,49,51) |
| RET | 0 | 2 | (43,49) |
| ROS1 | 0 | 0 | (43,49) |
| Amplification | |||
| MYC | 18–30 | 23 | (41,45,54) |
| ERBB2 | 0–36 | 0–27 | (42,49,55) |
| p16/CDKN2 | |||
| Homozygous deletion | 0–1 | N/A | (55,56) |
| Methylation | 0 | 30 | (31) |
*, combined small cell carcinomas are excluded. SCLC, small cell lung carcinoma; LCNEC, large cell neuroendocrine carcinoma; N/A, not applicable.